PaxMedica Acquires Suramin Research Assets From Rediscovery Life Sciences To Accelerate NDA Submission For PAX-101; No Financial Terms Disclosed
Portfolio Pulse from Benzinga Newsdesk
PaxMedica, Inc. (NASDAQ:PXMD) has acquired suramin research assets from Rediscovery Life Sciences (RLS). The assets will be used to support the submission for the approval of PAX-101, a treatment for African Sleeping Sickness. The acquisition follows PaxMedica's recent Type B meeting with the FDA and is expected to expedite the NDA submission process for PAX-101.
October 31, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PaxMedica's acquisition of suramin research assets from RLS is expected to expedite the NDA submission process for PAX-101, potentially leading to earlier approval and market entry.
The acquisition of suramin research assets from RLS is directly related to PaxMedica's core business and its ongoing efforts to get PAX-101 approved. This could potentially expedite the approval process, leading to earlier market entry and revenue generation for PaxMedica, which would likely have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100